Targeting malignancies with disulfiram (Antabuse): multidrug resistance, angiogenesis, and proteasome
Language English Country Netherlands Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
21247389
DOI
10.2174/156800911794519806
PII: EPub-Abstract-CCDT-105
Knihovny.cz E-resources
- MeSH
- Drug Resistance, Neoplasm MeSH
- Disulfiram therapeutic use MeSH
- Protease Inhibitors therapeutic use MeSH
- Proteasome Inhibitors * MeSH
- Clinical Trials as Topic MeSH
- Humans MeSH
- Drug Resistance, Multiple * MeSH
- Neoplasms drug therapy metabolism MeSH
- Neovascularization, Pathologic drug therapy MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Disulfiram MeSH
- Protease Inhibitors MeSH
- Proteasome Inhibitors * MeSH
An old drug, Antabuse (disulfiram), used for decades in alcohol aversion therapy, and its metabolite Ditiocarb were shown from 1970s to suppress cancer growth in vivo and even in human patients. The drug targets multidrug resistance, angiogenesis, invasion, and proteasome. Today, there are ongoing clinical trials of Antabuse as an adjuvant therapy against lung cancer and as a monotherapy against cancers metastasizing to liver. The larger clinical trials, if appropriate, will need support from governments and charities to get the generic drug into the clinic as a "non-profit" drug.
References provided by Crossref.org
The Promiscuity of Disulfiram in Medicinal Research
Multiple deadlocks in the development of nonprofit drugs
Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4
